Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, an 11% increase year-over-year on a GAAP basis and a 10% increase on a constant currency basis [5][6] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7] - Non-GAAP EPS grew by 12%, exceeding expectations, and free cash flow reached $74 million, a 13% increase year-over-year [8][19] - For the full year 2025, constant currency revenue growth was 11%, with a non-GAAP operating margin of 20.3% and free cash flow exceeding $215 million [9][19] Business Line Data and Key Metrics Changes - Q4 revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, while Peripheral Intervention products saw a 13% increase [11][12] - Sales of OEM products decreased by 15%, attributed to inventory destocking and macroeconomic factors [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales grew by 6% [16] - Organic constant currency growth in the U.S. was 8%, and 4% internationally [16] Company Strategy and Development Direction - The company aims for solid constant currency growth and non-GAAP operating margin expansion in 2026, with a focus on executing its Continued Growth Initiatives program [9][10] - The divestiture of the DualCap product line is expected to enhance manufacturing capacity and free up resources for higher-margin products [24][40] - The company is prioritizing R&D efforts and exploring M&A opportunities to drive growth [39][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the global macro environment but expressed optimism about the company's performance and future growth [9][10] - The CEO emphasized the importance of internal feedback and engagement with stakeholders to inform strategic decisions [30][33] Other Important Information - The company expects free cash flow of at least $200 million in 2026, with planned capital expenditures of approximately $90 million [27][55] - The anticipated impact of tariffs on non-GAAP EPS for 2026 is approximately $15 million [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management highlighted the focus on product mix, pricing discipline, and cost management as key drivers for gross margin improvement [43][46] Question: How is the WRAPSODY product performing in the market? - Management acknowledged that initial revenue expectations for WRAPSODY were not met but expressed confidence in achieving the $7 million revenue target for 2026 [48][50] Question: What are the strategic areas for M&A? - The company is looking at both foundational and therapeutic products for potential acquisitions, aiming to fill gaps in their product offerings [58][59] Question: What is the impact of the DualCap divestiture on margins and EPS? - The divestiture is expected to have a minimal EPS impact but will create a 140 basis point headwind to revenue growth [81][84]

Core Insights - The Chinese medical device industry has undergone significant transformation since the country joined the WTO in 2001, leading to the establishment of a comprehensive network of sales, service, and training by multinational manufacturers [1][2] - The domestic production of medical devices has increased dramatically, with the localization rate of monitoring devices exceeding 85%, and the market share of Chinese medical devices in the global market is on the rise [2][3] - China's medical device sector is projected to grow, with over 35,000 production companies expected by the end of 2025 and a market size estimated to reach 1.22 trillion yuan [2] Industry Development - The medical device sector is a crucial pillar of healthcare, alongside medical services and pharmaceuticals, encompassing a wide range of products including diagnostic equipment and implants [1] - The emergence of numerous startups focused on independent research and development of medical devices has been driven by market demand [1] - The Chinese manufacturing industry has developed capabilities across nearly all categories of medical devices, with significant advancements in innovative products such as ECMO [3] Technological Advancements - The integration of advanced technologies such as artificial intelligence and 5G is expected to drive the next wave of innovation in medical devices, enabling new diagnostic and treatment methods [4] - The establishment of research and development centers by foreign companies in China highlights the strategic importance of the local market and supply chain [3] Market Dynamics - China's large population and diverse health needs are accelerating the pace of technological iteration in the global medical device industry [2] - The shift from "following" to "competing" and even "leading" in certain areas reflects the industry's evolution and the rise of "China Intelligent Manufacturing" [3]

Group 1 - The first China-Europe freight train of the Lunar New Year, X8426, departed from Shenzhen Pinghu South Station, carrying home appliances, electronic products, and cross-border e-commerce packages, and is expected to reach countries like Russia and Poland in 14 days [1] - Since the launch of the "Bay Area" China-Europe freight train on August 18, 2020, a total of 975 trains have been operated, transporting over 90,000 TEUs (Twenty-foot Equivalent Units) with a total value exceeding 3.1 billion USD, expanding from 1 to 27 regular routes covering 47 countries and regions [1] - The freight train service supports over 7,000 enterprises in the Greater Bay Area, enhancing their international logistics capabilities [1] Group 2 - The business manager of a Shenzhen-based biomedical technology company highlighted the importance of the freight train's stable service and customized solutions for timely delivery of precision medical equipment to European clients [1] - The manager of the Pinghu South Comprehensive Logistics Hub indicated plans to build a more efficient and convenient international logistics platform to further reduce the comprehensive costs of cross-border trade for enterprises [1]

Group 1 - The article highlights the commencement of major projects and the resumption of production across various regions in China, emphasizing a strong start to the year following the Spring Festival [2][7]. - Guangdong Province's high-quality development conference sets a consistent theme of "collaborative development of manufacturing and services" for the year, aiming to drive innovation and modern industrial system construction [3]. - Multiple regions, including Shenzhen and Nanjing, are implementing new policies to enhance the business environment and support enterprises, showcasing a commitment to economic growth and development [4]. Group 2 - The article reports on the rapid recovery of production capacity in construction projects, such as the Lanzhang High-speed Railway, utilizing efficient operational models to meet ambitious targets [6]. - Various local governments are organizing job fairs and employment services to facilitate job placements, with significant participation and outcomes reported, such as over 1,000 employment intentions in Anhui [8]. - The focus on innovation is evident, with companies like 图湃 (Tupai) and 黑龙江瓷 (Heilongjiang Porcelain) investing in advanced technologies and new product development to enhance competitiveness in their respective fields [10][11].

Core Viewpoint - The announcement highlights that Sino Medical Technology Co., Ltd.'s subsidiary, Sino Shenchang Medical Technology Co., Ltd., has received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, marking a significant milestone for the company in entering the European market [2][5]. Group 1: Certification Details - The Ghunter intracranial thrombectomy stent was registered under the EU Medical Devices Regulation (EU) 2017/745 and has received the EU CE MDR certification [2]. - The product is designed for the removal of thrombus in large vessels of ischemic stroke patients within 24 hours of symptom onset, and it is a single-use device with a shelf life of 2 years [3][4]. - The certification includes an EU Quality Management System Certificate and an EU Technical Documentation Assessment Certificate, with the certificate issued on February 18, 2026, and expiring on February 1, 2031 [4]. Group 2: Product Features - The Ghunter stent features a full visualization design for improved surgical visibility, a curled design for better wall adherence and thrombosis capture, and various mesh sizes to enhance its ability to capture different types of thrombus [4]. - The product has already received a medical device registration certificate from the National Medical Products Administration of China in April 2023 [4]. Group 3: Impact on the Company - The certification signifies that Sino Shenchang has established a quality management system compliant with EU MDR requirements, allowing the stent to meet the latest market entry conditions in the EU [5]. - This approval is expected to positively impact the promotion and sales of the company's products in relevant markets, enhancing the company's market competitiveness and future operations [5].

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA was positive at $5.5 million, compared to a loss of $13.1 million in Q4 2024 [4][24] - The ending cash balance for 2025 was $75.6 million, indicating no need for additional capital [4] Business Line Data and Key Metrics Changes - U.S. Motiva revenue in 2025 was $45.6 million, contributing significantly to overall growth [3] - Gross margin for Q4 was 70.5%, a 200 basis point increase from the previous year, with overall gross profit margin increasing 330 basis points in 2025 [22][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global total sales in Q4, with strong growth in direct markets [22] - Latin America represented 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific accounted for 14.1% of sales, with improved performance in China [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a focus on minimally invasive procedures like Preservé [6][12] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market penetration [11][26] - The introduction of Motiva implants for breast reconstruction is expected to double the total addressable market in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and expects significant growth in 2027 [4][30] - The U.S. market remains healthy, with strong demand for breast augmentation procedures and a positive outlook for the minimally invasive portfolio [52][60] - The company is focused on maintaining operational momentum while preparing for future growth phases [20][21] Other Important Information - The company is actively working on FDA approvals for new products, including smaller sizes and reconstruction options, which are expected to enhance market share [18][69] - Establishment Labs is also considering refinancing options for its credit facility as it approaches the end of its term [26] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management noted strong early experiences with Preservé and Mia, indicating a positive trajectory for market growth and patient interest [33][35] Question: U.S. revenue and sales representative expansion - The company is focused on hiring experienced sales representatives to enhance market penetration and drive growth [36][38] Question: Plans for reconstruction market entry - Management highlighted the significant opportunity in the reconstruction market, with plans to expand the sales force and leverage existing relationships [40][41] Question: International growth and underlying demand - Management confirmed that international markets are showing healthy demand, with no significant one-off factors affecting growth [43][44] Question: Global market conditions and augmentation procedures - The overall market for breast augmentation procedures is healthy, with increasing interest and demand across various regions [51][54] Question: Contribution of pipeline products to revenue guidance - Reconstruction is expected to be more of a 2027 story, while Preservé is anticipated to drive significant revenue growth in 2026 [68][70]

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA for Q4 was $5.5 million, improving from a loss of $13.1 million in Q4 2024 [4][24] - Gross margin for Q4 was 70.5%, a 200 basis point increase from 68.5% in the previous year, with an overall gross profit margin increase of 330 basis points for 2025 compared to 2024 [22][23] Business Line Data and Key Metrics Changes - US Motiva revenue in 2025 was $45.6 million, significantly exceeding expectations, contributing to approximately 20% market share by the end of 2025 [5][6] - The minimally invasive breast augmentation platform, Preserve, is expected to generate over $30 million in demand in 2026, with strong early adoption and interest from both patients and surgeons [15][20] - The company has onboarded over 1,500 accounts since the launch of Motiva, with continued growth in the number of practices [9][11] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global sales in Q4, with over 20% growth in direct markets [22][23] - Latin America contributed 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific represented 14.1% of sales, with improved performance in China noted as a key focus area [22][19] Company Strategy and Development Direction - The company aims to expand its US sales force by adding up to 15 more representatives, focusing on experienced industry veterans to drive market penetration [11][38] - Establishment Labs is positioning itself as a leader in breast aesthetics through innovation and a strong R&D pipeline, with plans to introduce new products and expand into reconstruction markets [6][17] - The company is actively working on FDA approvals for new products, including Motiva implants for breast reconstruction, which could double the total addressable market in the US [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026, with expectations for significant earnings growth in 2027 and beyond [4][30] - The overall market for breast augmentation procedures is healthy, with increasing interest and demand noted from both patients and surgeons [52][54] - The company is focused on maintaining operational momentum while ensuring strong leadership and oversight for future growth initiatives [20][21] Other Important Information - The company has a strong cash balance of $75.6 million, indicating no immediate need for additional capital [4][26] - Establishment Labs is working towards inclusion in various indices, including the Russell, which could enhance visibility and shareholder value [28] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management highlighted strong early experiences with Preserve and Mia, indicating optimism for market growth and potential to double breast augmentation procedure volumes [33][35] Question: Plans for expanding the US sales force - The company is focused on hiring experienced reps from the industry, which is expected to drive productivity and market share growth [36][38] Question: Insights on the reconstruction market and FDA approval - Management indicated that reconstruction is likely a 2027 story, with strong interest from hospitals already noted [40][42] Question: International growth and underlying demand - Management confirmed that international markets are performing well, with no significant one-offs affecting growth, and demand remains stable [43][45] Question: Global market outlook and macroeconomic conditions - Management noted that the underlying markets are healthy, with strong growth in both US and international markets, particularly in direct markets [51][54] Question: Contribution of new products to revenue guidance - Management indicated that while reconstruction may not significantly impact 2026, Preserve is expected to drive substantial revenue growth [68][70] Question: Spending cadence and operational expenses - Management expects spending to be non-linear, with a potential increase in the back half of the year as they support US expansion [72][74]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP Adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. Limb Reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][5] Market Data and Key Metrics Changes - U.S. Limb Reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered strong sequential fourth quarter growth, reaching 7%, more than double the market rate [8] - The company expects to return to double-digit growth in the second half of 2026 for U.S. Limb Reconstruction as portfolio refinements take hold [14] Company Strategy and Development Direction - The company has rebranded its orthopedics business as Limb Reconstruction, focusing on high-value clinical categories with an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization, extending the timeline to 2028 [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by a focused distributor network and innovation pipeline [11][25] - The company is committed to disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [24][27] - Management highlighted the importance of ongoing product launches and enhancements across all business segments to drive sustained momentum [26] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted gross margins for the full year 2026 are expected to be approximately 72.5% [18] - The company anticipates $45 million-$50 million in capital expenditures for the year [22] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [32] Question: Long-range plan and margin improvement - Management explained that the extended timeline reflects the need for a stronger foundation and focus on market execution, with ongoing efforts to improve gross margins and cash generation [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with a return to double-digit growth in the second half of 2026 for limb reconstruction [42] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and emphasized a renewed focus on advancing the biologics portfolio [51][52] Question: Tariff impact and legal settlements - Management indicated an expected $1 million-$2 million impact from tariffs in 2026 and confirmed that an accrual for a legal settlement was taken in Q3 [57][62]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [12] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4] - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [13] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The spine commercial channel optimization efforts led to a 25% year-over-year growth in net sales from the top 30 U.S. distributor partners [5] Company Strategy and Development Direction - The company has rebranded its orthopedics business as limb reconstruction, focusing on four high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by new product launches and improved distributor performance [11] - The company expects to deliver durable top-line growth, expanding margins, and strong free cash flow in 2026 [9] - Management highlighted the importance of disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [22] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [16] - Adjusted growth margins for the full year are expected to be approximately 72.5% [19] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [31] Question: Long-range plan (LRP) and margin improvement - Management indicated that the delay in the LRP reflects the extensive work done to strengthen the foundation and optimize the distributor transition [32][33] - They emphasized the focus on gross margin expansion and productivity improvements to achieve mid-teens EBITDA and positive free cash flow [35] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [40] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and expressed confidence in the biologics portfolio's potential for recovery and growth [48][50] Question: Tariff impact and legal settlements - Management confirmed that the tariff impact is included in the 2026 guidance, expecting about $1 million-$2 million impact [54] - They acknowledged having taken an accrual for a legal settlement in Q3 [56]